How Analysts View Agios Pharmaceuticals and Peers in March 2018
Agios Pharmaceuticals (AGIO) is a biopharmaceutical company with therapeutic focus areas of cancer and rare genetic diseases. Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one analyst gave it a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.